KR20220061945A - Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물 - Google Patents

Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물 Download PDF

Info

Publication number
KR20220061945A
KR20220061945A KR1020227002902A KR20227002902A KR20220061945A KR 20220061945 A KR20220061945 A KR 20220061945A KR 1020227002902 A KR1020227002902 A KR 1020227002902A KR 20227002902 A KR20227002902 A KR 20227002902A KR 20220061945 A KR20220061945 A KR 20220061945A
Authority
KR
South Korea
Prior art keywords
alkyl
mmol
compound
cancer
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227002902A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 스페리
알란 엑스. 샹
저스틴 티. 에른스트
지크프리트 하. 라이히
폴 에이. 스프렌겔러
마이크 샤그하피
테오 마이클스
크리스티안 닐류스키
친 비엣 트란
개릭 케니스 패커드
알란 그룹스
카베리 우르칼란
다카스케 무카이야마
Original Assignee
이펙터 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이펙터 테라퓨틱스, 인크. filed Critical 이펙터 테라퓨틱스, 인크.
Publication of KR20220061945A publication Critical patent/KR20220061945A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227002902A 2019-07-02 2020-06-30 Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물 Ceased KR20220061945A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869,662 2019-07-02
PCT/US2020/040299 WO2021003157A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
KR20220061945A true KR20220061945A (ko) 2022-05-13

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002902A Ceased KR20220061945A (ko) 2019-07-02 2020-06-30 Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물

Country Status (15)

Country Link
US (2) US11286268B1 (https=)
EP (1) EP3994139A1 (https=)
JP (1) JP7595055B2 (https=)
KR (1) KR20220061945A (https=)
CN (1) CN114269756B (https=)
AR (1) AR119339A1 (https=)
AU (1) AU2020299362B2 (https=)
BR (1) BR112021026682A2 (https=)
CA (2) CA3085255A1 (https=)
CL (1) CL2021003573A1 (https=)
IL (1) IL289456A (https=)
PY (1) PY2031844A (https=)
TW (1) TWI748541B (https=)
UY (1) UY38773A (https=)
WO (1) WO2021003157A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
JP2023554521A (ja) 2020-12-22 2023-12-27 ファイザー・インク Ｅｉｆ４ｅ阻害剤の固体形態
JP2025539263A (ja) * 2022-11-10 2025-12-04 リボメトリックス，インコーポレイティド ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014179237A1 (en) 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法

Also Published As

Publication number Publication date
CN114269756A (zh) 2022-04-01
CA3188446A1 (en) 2021-01-07
AU2020299362A1 (en) 2022-02-24
PY2031844A (es) 2021-04-19
TWI748541B (zh) 2021-12-01
JP7595055B2 (ja) 2024-12-05
CA3085255A1 (en) 2021-01-02
WO2021003157A1 (en) 2021-01-07
IL289456A (en) 2022-02-01
JP2022539256A (ja) 2022-09-07
AR119339A1 (es) 2021-12-09
UY38773A (es) 2021-01-29
BR112021026682A2 (pt) 2022-03-15
CL2021003573A1 (es) 2022-08-12
US11286268B1 (en) 2022-03-29
TW202115058A (zh) 2021-04-16
CN114269756B (zh) 2024-05-14
EP3994139A1 (en) 2022-05-11
US20230108594A1 (en) 2023-04-06
AU2020299362B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
CN114269756B (zh) 抑制eif4e的4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物
US20210338673A1 (en) Mnk inhibitors and methods related thereto
US10112955B2 (en) Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
US11014926B2 (en) Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601